Consensus Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
31.25 ^USD	-0.89%		+6.36%	+134.96%

May. 23	Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing	MT
May. 22	Dyne Therapeutics Prices $325.5 Million Common Stock Offering	MT

Evolution of the average Target Price on Dyne Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e5ef4fbaaf718fe1030e0199d78d.29wP0xNmiI3u2F0YW55fVuiYxYeJUiQ0wA61gkx7UIE.toZ5_nIU5dre4DxOF_JqB6P6q7fIAGJxrWztyS0aB7msm3aMYFHK5JTuKg~dc0bc49b03469c5cd0170ba8128a0928

Analyst Recommendations on Dyne Therapeutics, Inc.

Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing	May. 23	MT
Dyne Therapeutics Prices $325.5 Million Common Stock Offering	May. 22	MT
Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept	May. 21	MT
HC Wainwright Adjusts Price Target on Dyne Therapeutics to $48 From $46, Maintains Buy Rating	May. 20	MT
Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target	Apr. 30	MT
Chardan Raises Price Target on Dyne Therapeutics to $31 From $20 on Increased Confidence in Lead Assets for DM1, DMD, Keeps Buy Rating	Mar. 08	MT
Piper Sandler Adjusts Price Target on Dyne Therapeutics to $29 From $27, Maintains Overweight Rating	Mar. 06	MT
Stifel Adjusts Price Target on Dyne Therapeutics to $41 From $35, Maintains Buy Rating	Mar. 06	MT
Oppenheimer Adjusts Dyne Therapeutics Price Target to $47 From $44, Maintains Outperform Rating	Mar. 05	MT
H.C. Wainwright Initiates Dyne Therapeutics With Buy Rating, Price Target is $36	Feb. 20	MT
Raymond James Adjusts Price Target on Dyne Therapeutics to $56 From $27, Keeps Strong Buy Rating	Jan. 04	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Traders Await Rate Cut Hints in Policy Meeting Readout	Jan. 03	MT
Chardan Adjusts Price Target on Dyne Therapeutics to $20 From $17, Maintains Buy Rating	23-03-03	MT
Raymond James Upgrades Dyne Therapeutics to Strong Buy From Outperform, Adjusts Price Target to $27 From $16	23-02-27	MT
Oppenheimer Initiates Coverage on Dyne Therapeutics With Outperform Rating, $34 Price Target	23-02-15	MT
Guggenheim Starts Dyne Therapeutics at Buy With $33 Price Target	23-01-26	MT
JPMorgan Adjusts Price Target on Dyne Therapeutics to $18 From $24, Maintains Overweight Rating	22-11-29	MT
Raymond James Adjusts Price Target on Dyne Therapeutics to $16 From $15, Maintains Outperform Rating	22-11-04	MT
Chardan Research Initiates Coverage on Dyne Therapeutics With Buy Rating, $17 Price Target	22-07-20	MT
Raymond James Starts Dyne Therapeutics at Outperform With $15 Price Target	22-07-12	MT
Piper Sandler Lowers Dyne Therapeutics' Price Target to $12 From $16, Maintains Overweight Rating	22-05-23	MT